Nextcure Stock Price, News & Analysis

NextCure (Nasdaq: NXTC) closed a private placement PIPE on Nov 17, 2025 raising approximately $21.5 million in gross proceeds. The financing sold 708,428 common shares at $8.52 per share and pre-funded warrants to purchase up to 1,815,049 shares at $8.519 each.

Led by Ikarian Capital, Squadron Capital Management, Affinity Healthcare Fund, and Exome Asset Management, with H.C. Wainwright as placement agent, the net proceeds are intended for general working capital and to extend the company’s cash runway into H1 2027, beyond planned H1 2026 proof‑of‑concept data readouts for ADC programs SIM0505 (CDH6) and LNCB74 (B7‑H4).

NextCure (Nasdaq:NXTC) announced a private placement to sell an aggregate of 2,523,477 shares of common stock (or pre-funded warrants) at $8.52 per share, priced at-the-market under Nasdaq rules, with expected gross proceeds of approximately $21.5 million. The offering is expected to close on or about November 13, 2025, subject to customary closing conditions, with H.C. Wainwright acting as exclusive placement agent.

The company said it intends to use net proceeds for general working capital, extending its cash runway into the first half of 2027, beyond the previously planned first half of 2026, and to support proof-of-concept data readouts for ADC programs SIM0505 (CDH6) and LNCB74 (B7-H4). The securities are offered under Section 4(a)(2)/Regulation D and will be registered for resale pursuant to a registration rights agreement.

NextCure (Nasdaq: NXTC) provided a business update and reported Q3 2025 results, highlighting ADC program progress and financing status. Key program milestones include U.S. enrollment for SIM0505 (CDH6 ADC) with first U.S. patient dosed in October 2025 and an anticipated proof-of-concept data readout for SIM0505 and LNCB74 (B7-H4 ADC) in the first half of 2026. NextCure acquired global rights to SIM0505 in June 2025 (ex-China) and received FDA acceptance of a protocol amendment for LNCB74 to add higher dose cohorts.

Financially, cash and marketable securities were $29.1M at 9/30/2025 versus $68.6M at 12/31/2024, reflecting a $39.5M decrease largely driven by operations and a $12.0M upfront license fee; management expects runway into mid-2026. Q3 R&D was $6.1M, G&A $2.8M, and net loss $8.6M.

NextCure (Nasdaq: NXTC) and Simcere Zaiming announced expansion of the ongoing Phase 1 trial of SIM0505 (CDH6 ADC) into the United States on Oct 16, 2025. The first U.S. patient was dosed at a mid-tier dose level where multiple responses have been observed, while dose escalation continues in China.

NextCure holds an exclusive global license (excluding Greater China) for SIM0505. The trial evaluates safety, tolerability, pharmacokinetics and efficacy in advanced solid tumors; current data are described as well tolerated with a favorable safety profile. Both companies expect to accelerate enrollment and aim to present proof-of-concept data in 1H 2026.

NextCure (Nasdaq: NXTC), a clinical-stage biopharmaceutical company focused on cancer therapies, will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference in New York City. The presentation is scheduled for Monday, September 8th, at 4:00 pm ET.

Investors can access the live audio webcast through the Investors section of NextCure's website. A replay will be available for 30 days following the event.

NextCure (Nasdaq: NXTC) reported Q2 2025 financial results and provided significant business updates. The company announced a strategic partnership with Simcere Zaiming for the Phase 1 program SIM0505 (CDH6 ADC), acquiring global rights excluding greater China. NextCure is advancing two key ADC programs: LNCB74 (currently in cohort 4) and SIM0505 (first US patient dosing expected this quarter).

Financial highlights include cash position of $35.3 million as of June 30, 2025, expected to fund operations into mid-2026. The company reported a net loss of $26.8 million for Q2 2025, largely due to a $17.0 million up-front license fee. Both ADC programs are expected to provide updates by Q4 2025 and proof of concept data in H1 2026.

NextCure (Nasdaq: NXTC) presented promising preclinical data for NC605, their novel anti-Siglec-15 antibody treatment for osteogenesis imperfecta (OI), also known as brittle bone disease. The study demonstrated that NP159 (the murine version of NC605) improved bone microarchitecture and reduced fracture incidence compared to anti-sclerostin treatment in OI mice.

Key findings showed that weekly treatment with 20 mg/kg of NP159 increased cortical and trabecular bone mineral density, tissue mineral density, and cortical thickness while decreasing trabecular separation compared to control groups. The research was conducted in collaboration with Dr. Cathleen Raggio from Hospital for Special Surgery, New York. NextCure is now seeking financial partners to advance NC605 toward an IND submission within 12-18 months.

NextCure (NXTC) and Simcere Zaiming announced a strategic partnership for SIM0505, a novel antibody-drug conjugate targeting CDH6 for solid tumors. NextCure gains global rights excluding Greater China, where Simcere Zaiming retains rights. SIM0505 is currently in Phase 1 trials in China, with U.S. trials expected to begin in Q3 2025. Initial Phase 1 data is anticipated in H1 2026. The deal includes access to Simcere's proprietary linker and TOPOi payload for NextCure's novel target ADC. SIM0505 features increased tumor binding compared to competitors and demonstrates robust anti-tumor activity. The agreement includes up to $745M in potential payments to Simcere Zaiming, including upfront payment, milestones, and tiered royalties up to double digits on net sales outside Greater China.

NextCure (NXTC) and LigaChemBio announced they will present a trial in progress poster for LNCB74, their B7-H4 targeted antibody-drug conjugate (ADC), at the upcoming ASCO Annual Meeting in Chicago. The Phase 1 study is evaluating LNCB74 as a monotherapy for advanced solid tumors, including platinum-resistant ovarian cancer, treatment-refractory breast cancer, endometrial cancer, biliary tract cancer, and squamous non-small cell lung cancer.

The first-in-human study includes dose escalation, safety, and biomarker backfills, followed by randomized dose expansion/optimization phases. The trial is currently in the dose escalation phase. According to NextCure's CMO, B7-H4 is an attractive target due to its high expression in multiple tumor types and limited expression in normal tissues. LNCB74 has shown promising preclinical results with a superior safety profile and potent anti-tumor activity.